Article Details
Retrieved on: 2017-12-13 18:52:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kyn Therapeutics, a biotechnology company advancing new immunometabolism therapies for treating cancer, today announced $49 million in Series A capital available to advance a pipeline of clinical- and pre-clinical stage therapies, including a program ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here